MonOct 5th, 2020
Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184, a Next-Generation, Targeted DNA-Damaging Agent
Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with [...]
TueSep 22nd, 2020
Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on Advancing the Development of LP-184 in Pancreatic Cancer
Lantern Pharma Announces Collaboration and Research Agreement with Fox [...]
ThuAug 27th, 2020
Lantern Pharma Announces Upcoming Conference Presentations
Lantern Pharma Announces Upcoming Conference Presentations Aug 27, 2020, [...]
ThuJul 30th, 2020
Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress
Lantern Pharma Reports Second Quarter 2020 Financial Results and [...]
FriJul 24th, 2020
Lantern Pharma to Host Second Quarter 2020 Operating and Financial Results Conference Call on July 30, 2020
Lantern Pharma to Host Second Quarter 2020 Operating and [...]
MonJul 20th, 2020
Lantern Pharma Establishes Manufacturing Network in Preparation for Its Phase 2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and a Phase 1 Clinical Trial for Solid Tumors and Glioblastoma
Lantern Pharma Establishes Manufacturing Network in Preparation for Its [...]